Pharmacological Basis of Differences in Dose Response, Dose Equivalence, and Duration of Action of Inhaled Corticosteroids
ConclusionIn a real-world clinical setting where there may be poor adherence to prescribed therapy, our findings suggest a significant therapeutic advantage for longer-acting ICS molecules in patients with asthma. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2024 Category: Drugs & Pharmacology Source Type: research
Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes
ConclusionsPrescribing more efficacious treatments earlier provides a greater opportunity to improve patient outcomes and minimizes treatment failures. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis
ConclusionNearly half of the patients initiating vibegron were adherent. Factors associated with adherence and persistence were more likely to be related to prescribing practices than patient characteristics. These results suggest it may be best to follow up with patients approximately 4 to 5 months after initiating treatment with vibegron. (Source: Advances in Therapy)
Source: Advances in Therapy - April 26, 2024 Category: Drugs & Pharmacology Source Type: research
The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs
ConclusionThese analyses support the use of precision epigenetic methods as part of the initial diagnosis and care of stable CHD and can meaningfully reduce cost. Real-world pilots to test the reliability of these analyses are indicated. (Source: Advances in Therapy)
Source: Advances in Therapy - April 25, 2024 Category: Drugs & Pharmacology Source Type: research
Development and Application of an Attribute-Based Taxonomy on the Benefits of Oral Anticoagulant Switching in Atrial Fibrillation: A Delphi Study
ConclusionsThe Delphi-based taxonomy identified five criteria for the beneficial effects of OAC switching, aiding in characterizing real-world OAC switching. (Source: Advances in Therapy)
Source: Advances in Therapy - April 24, 2024 Category: Drugs & Pharmacology Source Type: research
Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn ’s Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study
ConclusionsSubpopulations of biologic-naive patients with CD in whom vedolizumab appeared to have a larger effect relative to anti-TNF α agents for the outcome of clinical remission were identified. Validation of the identified subpopulations and simplified rules are warranted to confirm these findings.ClinicalTrials.gov IdentifierNCT03710486.Graphical Abstract available for this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - April 24, 2024 Category: Drugs & Pharmacology Source Type: research
Endovenous Microwave Ablation Versus Laser Ablation for Small Saphenous Vein Varicosis
ConclusionEMA and EVLA are equally effective treatment methods for SSV insufficiency. EMA is associated with higher NPRS scores in the early postoperative period. (Source: Advances in Therapy)
Source: Advances in Therapy - April 24, 2024 Category: Drugs & Pharmacology Source Type: research
Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients with Haemophilia B Without Inhibitors
ConclusionsrFIXFc prophylaxis provides improved health outcomes and lower costs, and represents a cost-effective treatment option compared with rFIX on-demand for adolescent and adult male patients with haemophilia B. This comparative assessment of cost-effectiveness should help to inform both clinicians and healthcare policy makers when making treatment decisions for patients with haemophilia B. (Source: Advances in Therapy)
Source: Advances in Therapy - April 23, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause
(Source: Advances in Therapy)
Source: Advances in Therapy - April 23, 2024 Category: Drugs & Pharmacology Source Type: research
Correction to: Association Between Bowel Wall Thickening and Long-Term Outcomes in Decompensated Liver Cirrhosis
(Source: Advances in Therapy)
Source: Advances in Therapy - April 23, 2024 Category: Drugs & Pharmacology Source Type: research
Primary Management of Operable Locally Advanced Oral Cavity Squamous Cell Carcinoma: Current Concepts and Strategies
ConclusionThe management strategy for LAOCSCC should be determined in a multidisciplinary setting with emphasis on tumor control, functional preservation, and quality of life of the patient. (Source: Advances in Therapy)
Source: Advances in Therapy - April 20, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023 —A Podcast
AbstractImmunotherapies have significantly improved outcomes in patients with multiple myeloma yet maintaining a durable response in heavily pretreated patients remains challenging. Therapies that target B cell maturation antigen (BCMA) provide additional treatment options in patients whose disease becomes refractory to several drug classes in early lines of therapy. Clinical trial data from selected patient populations and controlled settings are complemented by real-world data (RWD) from actual cl inical practice. In this podcast, the authors reviewed and discussed seven abstracts presented at the 65th Annual Meeting o...
Source: Advances in Therapy - April 20, 2024 Category: Drugs & Pharmacology Source Type: research
Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison
ConclusionEfgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab. (Source: Advances in Therapy)
Source: Advances in Therapy - April 20, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn ’s Disease in Italy
ConclusionThis analysis, carried-out in an Italian clinical setting, may help to optimise therapy for patients with UC and CD and provide relevant clinical practice data to inform decision-makers. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review
ConclusionRAM + PTX as a second-line treatment is effective and associated with an acceptable toxicity profile in patients with advanced or metastatic G/GEA in real-world settings of Japan and South Korea. More studies are recommended to further evaluate effectiveness and safety of RAM or RAM-based therapy, especially after anti-PD-1 therapy, in a wider Eastern Asian population.Trial RegistrationINPLASY registration number INPLASY2022120023. (Source: Advances in Therapy)
Source: Advances in Therapy - April 15, 2024 Category: Drugs & Pharmacology Source Type: research
